Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Venetoclax plus obinutuzumab improves quality of life in treatment-naive CLL: Prospective real-world insights from the verve study

Ingo Schwaner, Holger Hebart, Thomas Wolff, Caroline Lehmann, Eva Runkel, Burkhard Schmidt, Petra Pichler, Davide Rossi

Blood (2025) 146 (Supplement 1): 2117.

https://doi.org/10.1182/blood-2025-2117

Published: 2025

Journal Articles

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Blood (2025) 146 (Supplement 1): 3859.

https://doi.org/10.1182/blood-2025-3859

Published: 2025

Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Blood (2025) 146 (Supplement 1): 61.

https://doi.org/10.1182/blood-2025-61

Published: 2025

Journal Articles

Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria

Blood (2025) 146 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2025-4584

Published: 2025

Journal Articles

Randomized comparison between isatuximab-rd versus rd induction, followed by isa-R versus R maintenance in very elderly patients with NDMM: Efficacy data on MRD after induction (AGMT-MM04 Trial)

Blood (2025) 146 (Supplement 1): 2258.

https://doi.org/10.1182/blood-2025-2258

Published: 2025

Journal Articles

Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group

Blood (2025) 146 (Supplement 1): 48.

https://doi.org/10.1182/blood-2025-48

Published: 2025

Journal Articles

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Blood (2024) 144 (Supplement 1): 7511.

https://doi.org/10.1182/blood-2024-208073

Published: 2024

Journal Articles

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Blood (2024) 144 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2024-207230

Published: 2024

Journal Articles

Clinical Outcomes of CLL Patients Treated with Venetoclax Under Real-World Conditions in Austria, Germany, and Switzerland after Treatment with Ibrutinib

Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi

Blood (2024) 144 (Supplement 1): 6788.

https://doi.org/10.1182/blood-2024-200644

Published: 2024

Journal Articles

Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR)

Ella Willenbacher, Siegfried Sormann, Petra Pichler, Krauth Maria-Theresa, Hermine Agis, Irene Strassl, Klaus Podar, Roman Weger, Wolfgang Willenbacher

Blood (2024) 144 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2024-207776

Published: 2024

Journal Articles

Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA - Insights from a Prospective Real-World Study in Switzerland and Austria

Thomas Pabst, Thomas Lehmann, Petra Pichler, Sigrid Machherndl-Spandl, Michael Gregor, Jeroen S. Goede, Sabine Gerull, Daniel Maria Mayer, Jean-François Lambert, Catherine Germanier, Georg Stüssi

Blood (2024) 144 (Supplement 1): 2413.

https://doi.org/10.1182/blood-2024-193999

Published: 2024

Journal Articles

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi

Blood (2023) 142 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2023-174387

Published: 2023

Journal Articles

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)

Thomas Melchardt, Rebecca I Wurm-Kuczera, Bettina Altmann, Petra Pichler, Manuel Orlinger, Michael Panny, Luisa Wohn, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Richard Greil, Bjoern Chapuy

Blood (2023) 142 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2023-188854

Published: 2023

Journal Articles

Real-World Outcomes and Treatment Patterns in AL-Amyloidosis in Austria: An Analysis from the Austrian Interdisciplinary Amyloidosis Registry (AIDA)

Wolfgang Willenbacher, Hermine Agis, Maria-Theresia Krauth, Carlos Rodriguez-Torres, Irene Strassl, Nicolas Dominik Verheyen, Victoria Hoeller, Philpp Darling, Petra Pichler, Sarah Rittler, Roman Weger, Ella Willenbacher

Blood (2023) 142 (Supplement 1): 6749.

https://doi.org/10.1182/blood-2023-187598

Published: 2023

Journal Articles

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski

Blood (2023) 142 (16): 1348–1358.

https://doi.org/10.1182/blood.2023020637

Published: 2023

Includes: Supplemental data

Journal Articles

Ninreal - a Real World (RW) Comparison of Ixazomib Triplets and IMiD Duplets, in Relapsed and Refractory Multiple Myeloma (RRMM) from the Austrian Myeloma Registry (AMR)

Wolfgang Willenbacher, Petra Pichler, Irene Strassl, Maria-Theresa Krauth, Hermine Agis, Siegfried Sormann, Bernd L. Hartmann, Klaus Podar, Roman Weger, Ella Willenbacher

Blood (2022) 140 (Supplement 1): 13194–13195.

https://doi.org/10.1182/blood-2022-165366

Published: 2022

Journal Articles

Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve

Ingo Schwaner, Holger Hebart, Christoph Losem, Thomas Wolff, Kirsten Famulla, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi, Thomas Noesslinger

Blood (2022) 140 (Supplement 1): 12412–12413.

https://doi.org/10.1182/blood-2022-162273

Published: 2022

Journal Articles

First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Pérez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Bettina Brackertz, Neha Shah, Andrea Sporchia, John M. Burke, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 3556.

https://doi.org/10.1182/blood-2021-148354

Published: 2021

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

David Belada, MD PhD, Grzegorz S. Nowakowski, MD, Juan Miguel Bergua Burgues, MD, Marc André, MD, Katerina Kopeckova, MD, Don A. Stevens, MD, Marek Trněný, MD Prof, Ernesto Pérez Persona, Petra Pichler, Pia Klöpfer, Bettina Brackertz, Emanuel Lohrmann, MD, Anirban Lahiry, Neha Shah, Günter Fingerle-Rowson, MDPhD, Wolfram Brugger, John M. Burke, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139788

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Venetoclax plus obinutuzumab improves quality of life in treatment-naive CLL: Prospective real-world insights from the verve study

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria

Randomized comparison between isatuximab-rd versus rd induction, followed by isa-R versus R maintenance in very elderly patients with NDMM: Efficacy data on MRD after induction (AGMT-MM04 Trial)

Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven - Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Clinical Outcomes of CLL Patients Treated with Venetoclax Under Real-World Conditions in Austria, Germany, and Switzerland after Treatment with Ibrutinib

Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR)

Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA - Insights from a Prospective Real-World Study in Switzerland and Austria

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Real-World Outcomes and Treatment Patterns in AL-Amyloidosis in Austria: An Analysis from the Austrian Interdisciplinary Amyloidosis Registry (AIDA)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Ninreal - a Real World (RW) Comparison of Ixazomib Triplets and IMiD Duplets, in Relapsed and Refractory Multiple Myeloma (RRMM) from the Austrian Myeloma Registry (AMR)

Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve

First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only